Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

ClinicalTrials.gov ID: NCT00901901

Public ClinicalTrials.gov record NCT00901901. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 26, 2026, 11:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized trial to evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib once daily in subjects with unresectable advanced or metastatic Child-Pugh A HCC. Patients who are candidates for potentially curative intervention (i.e. surgical resection or local ablation) are not eligible for this study.

Study identification

NCT ID: NCT00901901
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 732 participants

Conditions and interventions

Conditions

Carcinoma, Hepatocellular

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 21, 2009 (Actual)
Primary completion: Apr 17, 2012 (Actual)
Completion: May 23, 2018 (Actual)
Last update posted: May 30, 2019

2009 – 2018

United States locations

U.S. sites: 23
U.S. states: 18
U.S. cities: 22

Facility	City	State	ZIP	Site status
Not listed	San Francisco	California	94115	—
Not listed	Washington D.C.	District of Columbia	20007	—
Not listed	Gainesville	Florida	32610	—
Not listed	Miami	Florida	33136	—
Not listed	Atlanta	Georgia	30318	—
Not listed	Honolulu	Hawaii	96817	—
Not listed	Maywood	Illinois	60153-5585	—
Not listed	Westwood	Kansas	66205	—
Not listed	Louisville	Kentucky	40202	—
Not listed	New Orleans	Louisiana	70112	—
Not listed	Baltimore	Maryland	21202	—
Not listed	Boston	Massachusetts	02114	—
Not listed	Boston	Massachusetts	02215-5450	—
Not listed	Worcester	Massachusetts	01655	—
Not listed	Detroit	Michigan	48202	—
Not listed	Minneapolis	Minnesota	55455	—
Not listed	New York	New York	10029	—
Not listed	Rochester	New York	14642	—
Not listed	Valhalla	New York	10595	—
Not listed	Charlotte	North Carolina	28203	—
Not listed	Philadelphia	Pennsylvania	19107	—
Not listed	Houston	Texas	77030	—
Not listed	Seattle	Washington	98109-1023	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00901901, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 30, 2019 · Synced Oct 26, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00901901 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →